Prolyl hydroxylase domain 3 influences the radiotherapy efficacy of pancreatic cancer cells by targeting hypoxia-inducible factor-1α
Open Access
- 1 November 2018
- journal article
- research article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 11, 8507-8515
Abstract
Purpose: Pancreatic cancer is characterized by a hypoxic microenvironment and resistance to most currently available treatment modalities. Prolyl hydroxylase domain 3 (PHD3) is a rate-limiting enzyme that regulates the degradation of hypoxia-inducible factors (HIFs) and is deregulated in pancreatic cancer cells. Whether such alteration of PHD3 expression contributes to the sustained growth and radioresistance of pancreatic cancer cells remains largely unknown. Materials and methods: PHD3 was overexpressed in pancreatic cancer Mia-paca2 cells via lentiviral expression. Cell cycle progression and apoptosis were assayed by flow cytometry. HIF-1α, EGFR, and PHD3 protein expression was assessed by Western blotting. Cell survival was determined in a colony formation assay. Results: PHD3 overexpression suppressed HIF-1α protein expression and EGFR phosphorylation and enhanced the 2 Gy irradiation-mediated reductions in HIF-1α and phosphorylated (p)-EGFR under either normoxic or hypoxic conditions. PHD3 overexpression inhibited the growth and colony formation of Mia-paca2 cells in response to irradiation under either normoxic or hypoxic conditions. PHD3 overexpression exacerbated irradiation-induced apoptosis, with a greater effect under hypoxia than normoxia. Cell cycle distribution analysis demonstrated that PHD3 overexpression resulted in further shortened S phase and lengthened G2/M phase in response to irradiation. Conclusion: PHD3 expression may contribute to the radiotherapy efficacy of pancreatic cancer cells and serve as a novel biomarker for improving radiotherapy efficacy in pancreatic cancer.Keywords
This publication has 38 references indexed in Scilit:
- Development of Inhibitors of the PAS-B Domain of the HIF-2α Transcription FactorJournal of Medicinal Chemistry, 2013
- Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapyTrends in Pharmacological Sciences, 2012
- Up-regulation of hypoxia inducible factor-1α by cobalt chloride correlates with proliferation and apoptosis in PC-2 cellsJournal of Experimental & Clinical Cancer Research, 2012
- Expression of oncogenic K‐ras and loss of Smad4 cooperate to induce the expression of EGFR and to promote invasion of immortalized human pancreas ductal cellsInternational Journal of Cancer, 2010
- The role of HIF prolyl hydroxylases in tumour growthJournal of Cellular and Molecular Medicine, 2010
- Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeuticsMolecular Cancer, 2010
- Regulation of cancer cell metabolism by hypoxia-inducible factor 1Seminars in Cancer Biology, 2009
- Radiotherapy for Locally Advanced Pancreatic CancerJournal of Clinical Oncology, 2007
- C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl HydroxylationCell, 2001
- Regulation of the release of tumour necrosis factor (TNF)α and soluble TNF Receptor by γ irradiation and interferon γ in Ewing's sarcoma/peripheral primitive neuroectodermal tumour cellsJournal of Cancer Research and Clinical Oncology, 1997